What's Going On With ASLAN Pharmaceuticals Stock Today?
Portfolio Pulse from Vandana Singh
ASLAN Pharmaceuticals Ltd (NASDAQ:ASLN) released topline data from its TREK-AD Phase 2b study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis. The drug met the primary endpoint in three dosing arms with statistical significance. However, the 400mg Q4W dosing arm did not meet the primary or secondary endpoints. Further data is expected in Q4 2023 and a Phase 3 clinical development program is planned for 2024. ASLN shares were down by almost 14% in the premarket but have since recovered.
July 06, 2023 | 1:09 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
ASLAN Pharmaceuticals' eblasakimab met the primary endpoint in its Phase 2b study, but one dosing arm did not meet the primary or secondary endpoints. This mixed result, along with the anticipation of further data, may have contributed to the initial drop in ASLN's stock price.
The mixed results from the Phase 2b study of eblasakimab likely caused uncertainty among investors, leading to the initial drop in ASLN's stock price. However, the recovery suggests that investors may be optimistic about the drug's future prospects, especially given the positive results in other dosing arms and the planned Phase 3 clinical development program.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100